Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

  • Adam Feuerstein

By Adam Feuerstein March 11, 2020

Reprints
transmission electron micrograph covid19
Courtesy NIAID-RML

Biotech: Disrupted.

As the number of Covid-19 cases expand globally, every corner of the biotech industry will be impacted in some way. There will be office interruptions, delays in drug development and clinical trials, extensions of regulatory reviews, and limits on new drug launches. Sales of certain older drugs will drop along with prescriptions. Expect investor and financing challenges, too.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Marburg fever outbreak in Equatorial Guinea widens, WHO reports
Marburg fever outbreak in Equatorial Guinea widens, WHO reports
Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
Stéphane Bancel, Bernie Sanders spar over what Moderna owes…
Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government
Pharmalittle: FDA panel backs conditional approval for Biogen ALS…
Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

  • Adam,

    Why worry about Italy? So what if all the clincal trails in that country girnds to a halt? I am sure you know as well as I do that among the Big 5 EU nations as a drug market (UK, Germany, France, Spain and Italy), Italy with only barely 60 million people is a small fraction with insignificant revenue for any new drug and also for any existing drug sold in that country. So what if any new drug is NOT approved in Italy. Big deal. Patients in dire needs can always drive across the border to get it!

Comments are closed.

Recommended Stories